Literature DB >> 18729777

Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants.

Wendy A Keitel1, Robert L Atmar, Diane Nino, Thomas R Cate, Robert B Couch.   

Abstract

Immunization approaches that will broaden antibody responses to antigenically different variants of influenza viruses are needed because vaccine strains do not always match the viruses that circulate during the subsequent epidemic. Sera collected from subjects who were vaccinated with various doses of influenza A/Taiwan/86 vaccine were assayed for the levels of antibody against 3 subsequent, antigenically different, A/H1N1 variants. Dose-related increases in antibody responses to all 4 viruses were observed, even against a virus appearing >10 years after vaccination. Increasing the influenza vaccine dosage safely and predictably enhanced antibody responses to the vaccine virus and to subsequent, antigenically different, influenza A/H1N1 variants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729777     DOI: 10.1086/591465

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

Review 2.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

3.  Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Authors:  Patricia M Flynn; Sharon Nachman; Petronella Muresan; Terence Fenton; Stephen A Spector; Coleen K Cunningham; Robert Pass; Ram Yogev; Sandra Burchett; Barbara Heckman; Anthony Bloom; L Jill Utech; Patricia Anthony; Elizabeth Petzold; Wende Levy; George K Siberry; Ruth Ebiasah; Judi Miller; Edward Handelsman; Adriana Weinberg
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

4.  Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.

Authors:  Hana M El Sahly; Robert L Atmar; Shital M Patel; Abbie Bellamy; Liwei Liu; Wenshan Hong; Huachen Zhu; Yi Guan; Wendy A Keitel
Journal:  Vaccine       Date:  2019-04-04       Impact factor: 3.641

5.  High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.

Authors:  Jack T Stapleton; Nancy Wagner; Rebecca Tuetken; Abbie R Bellamy; Heather Hill; Sonnie Kim; Patricia L Winokur
Journal:  Vaccine       Date:  2020-04-12       Impact factor: 3.641

6.  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Authors:  Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

7.  Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.

Authors:  Karen L Kotloff; Natasha B Halasa; Christopher J Harrison; Janet A Englund; Emmanuel B Walter; James C King; C Buddy Creech; Sara A Healy; Rowena J Dolor; Ina Stephens; Kathryn M Edwards; Diana L Noah; Heather Hill; Mark Wolff
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.